Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer.
Lee HO, Hong Y, Etlioglu HE, Cho YB, Pomella V, Van den Bosch B, Vanhecke J, Verbandt S, Hong H, Min JW, Kim N, Eum HH, Qian J, Boeckx B, Lambrechts D, Tsantoulis P, De Hertogh G, Chung W, Lee T, An M, Shin HT, Joung JG, Jung MH, Ko G, Wirapati P, Kim SH, Kim HC, Yun SH, Tan IBH, Ranjan B, Lee WY, Kim TY, Choi JK, Kim YJ, Prabhakar S, Tejpar S, Park WY. Lee HO, et al. Among authors: kim yj, kim sh, kim ty, kim n, kim hc. Nat Genet. 2020 Jun;52(6):594-603. doi: 10.1038/s41588-020-0636-z. Epub 2020 May 25. Nat Genet. 2020. PMID: 32451460
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Lee J, et al. Among authors: kim km, kim tw, kim ty, kim kp, kim sh, kim hc. Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Invest New Drugs. 2014. PMID: 24468885 Clinical Trial.
Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Lee J, et al. Among authors: kim km, kim tw, kim ty, kim kp, kim sh, kim hc. Invest New Drugs. 2015 Feb;33(1):269-70. doi: 10.1007/s10637-014-0162-x. Invest New Drugs. 2015. PMID: 25236593 No abstract available.
Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
Lee SH, Lee B, Shim JH, Lee KW, Yun JW, Kim SY, Kim TY, Kim YH, Ko YH, Chung HC, Yu CS, Lee J, Rha SY, Kim TW, Jung KH, Im SA, Moon HG, Cho S, Kang JH, Kim J, Kim SK, Ryu HS, Ha SY, Kim JI, Chung YJ, Kim C, Kim HL, Park WY, Noh DY, Park K. Lee SH, et al. Among authors: kim yh, kim ji, kim tw, kim hl, kim ty, kim sy, kim c, kim sk, kim j. Cancer Res Treat. 2019 Jan;51(1):211-222. doi: 10.4143/crt.2018.132. Epub 2018 Apr 23. Cancer Res Treat. 2019. PMID: 29690749 Free PMC article.
2,571 results